Paper Details

  1. Home
  2. Paper Details

Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo.

Author: BurginChristie, JonesDan E, MastersBarbara K, ParkerDon E, Potter-KimballRobin, TuckerPhebe, WyattDorothy B

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effects of two selective serotonin reuptake inhibitors (SSRIs), citalopram and sertraline, compared to placebo on chronic posttraumatic stress disorder (PTSD). All three treatment groups improved significantly in PTSD symptoms and sleep time. However, there were subtle differences in improvements in PTSD symptom clusters, physiologic reactivity, and reported adverse events.
Paper Details　
Original Abstract of the Article :
Effects of double-blind treatment of chronic posttraumatic stress disorder (PTSD) with 2 SSRIs and placebo on emotional symptoms and autonomic reactivity were assessed prospectively. PTSD subjects received citalopram (n=25), sertraline (n=23), or placebo (n=10) for 10 weeks, with psychophysiologic a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/14608246

データ提供：米国国立医学図書館（NLM）

PTSD: A Personalized Approach to Treatment

Post-traumatic stress disorder (PTSD) is a debilitating condition that can significantly impact an individual's well-being. This study explores the effectiveness of two selective serotonin reuptake inhibitors (SSRIs), citalopram and sertraline, in treating chronic PTSD. The authors conducted a double-blind, placebo-controlled trial to assess the impact of these medications on emotional symptoms, autonomic reactivity, and reported side effects.

SSRIs: A Promising Class of Medications for PTSD

The study found that both citalopram and sertraline significantly improved symptoms of PTSD compared to placebo. While both medications demonstrated a class effect, subtle differences were observed in their impact on specific symptom clusters, physiological reactivity, and reported side effects. These findings suggest that individual patient characteristics may influence treatment response and that a personalized approach to SSRI selection may be beneficial.

Navigating the Nuances of PTSD Treatment

This study highlights the complex nature of PTSD and the need for individualized treatment strategies. The researchers emphasize that a one-size-fits-all approach is not always effective, and that a personalized approach, considering individual patient needs and response to treatment, is essential for optimizing outcomes. Ongoing research and monitoring are crucial to refine treatment approaches and improve the lives of individuals with PTSD.

Dr.Camel's Conclusion

Treating PTSD is like navigating a desert of emotional distress. This research, like a trusty compass guiding us through the complexities of PTSD management, sheds light on the potential of SSRIs as a treatment option. It reminds us that every individual with PTSD is unique, and their treatment journey requires a personalized approach, considering individual needs and responses to medication.

Date :
  1. Date Completed 2004-09-30
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

14608246

DOI: Digital Object Identifier

14608246

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.